ID BT 239 AC CVCL_WW54 SY BT239 DR PharmacoDB; BT239_129_2019 DR Wikidata; Q93432609 RX PubMed=25184684; RX PubMed=27723727; CC Characteristics: Low-passage-number culture. CC Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727). CC Derived from site: In situ; Brain; UBERON=UBERON_0000955. DI NCIt; C3058; Glioblastoma DI ORDO; Orphanet_360; Glioblastoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) CA Cancer cell line DT Created: 06-09-19; Last updated: 19-12-24; Version: 8 // RX PubMed=25184684; DOI=10.1371/journal.pone.0106694; PMCID=PMC4153667; RA Holmberg Olausson K., Maire C.L., Haidar S., Ling J., Learner E., RA Nister M., Ligon K.L.; RT "Prominin-1 (CD133) defines both stem and non-stem cell populations in RT CNS development and gliomas."; RL PLoS ONE 9:E106694-E106694(2014). // RX PubMed=27723727; DOI=10.1038/nbt.3697; PMCID=PMC5142231; RA Stevens M.M., Maire C.L., Chou N., Murakami M.A., Knoff D.S., RA Kikuchi Y., Kimmerling R.J., Liu H.-Y., Haidar S., Calistri N.L., RA Cermak N., Olcum S., Cordero N.A., Idbaih A., Wen P.Y.-C., RA Weinstock D.M., Ligon K.L., Manalis S.R.; RT "Drug sensitivity of single cancer cells is predicted by changes in RT mass accumulation rate."; RL Nat. Biotechnol. 34:1161-1167(2016). //